- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02230891
Biomarker Guided Therapies in Stage A/B Heart Failure
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recently the investigators have shown that HF risk prediction can be improved using cardiac troponin T measured with a novel high-sensitivity assay (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Furthermore, hs-cTnT seems to identify individuals at higher risk among those with established risk factors (such as hypertension) for HF. In preliminary results, the investigators have shown that individuals with systolic blood pressure of 120-129 mm Hg and elevated hs-cTnT have a higher rate of incident HF than those with systolic blood pressure of 140-159 mm Hg and undetectable hs-cTnT. Therefore, the investigators believe that by using hs-cTnT to estimate HF risk the investigators can identify individuals in whom aggressive modification of risk factors such as high blood pressure will be associated with a favorable risk-benefit ratio.
The investigators' objective/specific aim therefore is to evaluate if treatment of selected subjects with Stage A or B HF (i.e., those with hs-cTnT >5 ng/L and an estimated 10-year HF hospitalization risk of >5%) who have reasonably well-controlled blood pressure with antihypertensive agents (carvedilol or spironolactone) will be associated with improvement of surrogate markers associated with incident HF (i.e., speckle-tracked cardiac and vascular strain). Carvedilol and spironolactone were chosen for the following reasons: a) they are not routinely used as first-line antihypertensive agents; b) beta-blockade was associated with decreases in hs-cTnT in the preliminary analysis of subjects with established HF; and c) the mechanism of actions of carvedilol and spironolactone provide a sound scientific rationale for use in prevention of HF.
Using a prospective open-label blinded end point (PROBE) design, the investigators propose to randomize 210 subjects aged >40 years with systolic blood pressure between 120-155 mm Hg, cardiac troponin T (measured with a novel high-sensitivity assay) level >5 ng/L, and 10-year HF risk >5% (estimated using a validated laboratory model including demographic factors, NT-proBNP, and hs-cTnT) to receive carvedilol (nonselective beta-blocker), spironolactone (aldosterone antagonist), or usual care for 18 months. The primary end point will be change in global longitudinal systolic myocardial strain estimated using 2D speckle tracking. Additionally, changes in vascular strain and biomarkers will be evaluated. This study will help us identify whether both or either of the medications can be further tested in large randomized clinical trials to prevent the incidence of HF.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Michael E. DeBakey VA Medical Center, Houston, TX
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Only Veterans are eligible to participate. Other inclusion criteria include
- Age greater than 40 years
- One of the following in order to establish Stage A HF a. Hypertension b. Diabetes mellitus (controlled: defined as hemoglobin A1c less than 9%) c. Obesity (defined as BMI greater than 30 kg/m2) d. Metabolic syndrome (using the National Cholesterol Education Panel definition) e. Left ventricular hypertrophy (by ECG) f. Coronary or cerebrovascular arterial disease
- Troponin T measured by the high sensitivity assay of greater than 5ng/L
- Systolic BP 120-155 mmHg at primary care provider (PCP) visit and prerandomization visit (i.e., 2 separate confirmations of the same). If there is discordance between the PCP visit and pre-randomization the investigators will bring patient back to recheck his BP and use that as the tie breaker. Not orthostatic with measurements (defined as a fall in systolic BP greater than 20 mmHg when subjects assume an upright position). - Estimated 10-yr HF risk (based on Atherosclerosis Risk in Communities HF Lab model) greater than 5%
- Provides informed consent
Exclusion Criteria:
The exclusion criteria include
- Active Atrial fibrillation
- History of chest/ neck radiation
- High-risk chronic obstructive pulmonary disease (COPD) (GOLD classification 3-4 with greater than equal to 2 COPD exacerbations in the last 12 months)
- Known allergy to carvedilol or spironolactone
- Renal insufficiency with estimated Glomerular Filtration Rate (eGFR) less than 60 ml/min
- Serum potassium greater than 5 meq/L
- Current use of carvedilol, spironolactone, any other beta-blockers or aldosterone antagonists
- Signs of clinical HF on initial examination (pulmonary rales/crackles, elevated jugular venous pulse with S3/S4 on auscultation)
- Left ventricular ejection fraction <50% by echo
- Moderate or greater valve stenosis or regurgitation
- Hypertrophic cardiomyopathy
- Exposure to known cardiotoxic chemotherapy
- Poor echo image quality
- Right ventricular dysfunction more than mild
- Any valvular dysfunction that is more than mild
- Any life-threatening disease expected to result in death within the next 2 years
- Active severe liver disease (evaluated at Visit 1): cirrhosis, active hepatitis, aspartate transaminase (ALT) or alanine transaminase (AST) greater than 3 x ULN, or biliary obstruction with hyperbilirubinemia (total bilirubin greater than 2 x ULN).
- Participation in another clinical trial involving an investigational agent within 90 days prior to randomization
- Any condition or therapy which, in the opinion of the investigator, might pose a risk to the patient or make participation in the study not in the patient s best interest
- Drug or alcohol abuse within the past 6 months, and unable/unwilling to abstain from drug abuse and excessive alcohol consumption during the study. Excessive alcohol consumption is on average greater than 2 units of alcohol per day. A unit of alcohol is defined as a 12-ounce (350 mL) beer, 5-ounce (150 mL) wine, or 1.5-ounce (45 mL) of 80 ]proof alcohol for drinks.
- Mental/psychological impairment or any other reason to expect patient difficulty in complying with the requirements of the study.
- Any immunosuppressed condition where intercurrent illnesses may affect interpretation of study results
- Pregnant women or any woman planning a pregnancy during the study period
- Not meeting any of the inclusion criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Carvedilol
Approximately 70 subjects will be randomized to carvedilol
|
Carvedilol is a non selective beta blocker
|
Active Comparator: Spironolactone
Approximately 70 subjects will be randomized to spironolactone
|
Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure
|
Other: Usual care
Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers
|
standard care as per primary care provider
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Cardiac Global Longitudinal Strain
Time Frame: 18 months
|
Change in myocardial speckle tracked strain (global longitudinal strain) after 18 months (baseline vs. 18 months) of therapy with carvedilol or spironolactone or usual care.
The myocardial global longitudinal strain was measured using echocardiography
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in NTproBNP (Biomarker)
Time Frame: 18 months
|
Change in levels of NT-proBNP (measured in blood samples) between baseline and 18 months after therapy with carvedilol or spironolactone or usual care
|
18 months
|
Change in Pulse Wave Velocity
Time Frame: 18 months
|
Changes in arterial stiffness between baseline and 18 months after therapy with carvedilol, spironolactone or usual care.
Arterial stiffness was measured by pulse wave velocity (Sphygmocor device)
|
18 months
|
Change in Troponin T Measured Using a High Sensitivity Assay
Time Frame: 18 months
|
Change in levels of troponin T (measured with a high sensitivity assay in blood samples) between baseline and 18 months after therapy with carvedilol or spironolactone or usual care
|
18 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Vijay Nambi, MBBS, Michael E. DeBakey VA Medical Center, Houston, TX
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Heart Failure
- Cardiovascular Diseases
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protective Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Hormone Antagonists
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Antioxidants
- Mineralocorticoid Receptor Antagonists
- Diuretics, Potassium Sparing
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Spironolactone
- Carvedilol
Other Study ID Numbers
- CLNB-009-13F
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BayerCompletedPrimary HypertensionChina
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Carvedilol
-
Chong Kun Dang PharmaceuticalCompletedHypertensionKorea, Republic of
-
Zunyi Medical CollegeUnknownChronic AppendicitisChina
-
E-DA HospitalTerminatedVariceal BleedingTaiwan
-
GlaxoSmithKlineCompletedMetabolic, CardiovascularUnited Kingdom
-
Andhra Medical CollegeCompleted
-
Institute of Liver and Biliary Sciences, IndiaRecruiting
-
Owen Chan, PhDTerminated
-
CTI-1, LLCGlaxoSmithKline; CTI Clinical Trial and Consulting ServicesCompletedCongestive Heart FailureUnited States
-
University of MinnesotaGlaxoSmithKlineCompletedPre-hypertensionUnited States
-
GlaxoSmithKlineCompletedHeart Failure, CongestiveJapan